92 research outputs found
Formation of psychological security of the educational environment (on the example of the school in the Altai Republic)
No full textThe article considers one of the topical and important issues of modern Russian education – formation of the psychological safety of the educational environment at school. The paper gives the modern interpretations of the definitions of «psychological safety» and «educational environment». The authors note that it is specially organized work that can promote constructive interaction between all subjects of the educational process, improvement of the psychological climate in the school environment, successful formation of psychological safety at school with a large or small number of pupils. In particular, the article presents the results of the study of the educational environment of one of the rural schools of the Altai Republic and also reviews the compiled and tested model of psychological and pedagogical conditions for formation of psychological safety, the directions of implementation of the developed model. In addition, the paper analyses the results of the effectiveness of this model
RISK FACTORS FOR OSTEOPOROSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS
No full textThe present review is devoted to the risk factors of osteoporosis progression in patients with rheumatoid arthritis (RA), both relevant and irrelevant to the main disease. It is assumed that the most important predictors of the bone mineral density decrease is severe course of RA, significant functional disability (according to HAQ), glucocorticoid therapy, elderly age, low body mass index and menopause. However, despite the vast amount of studies, results on the risk factors of osteoporosis remain ambiguous and require further investigation
SAT0534 Effect of sustained- release symptomatic drugs on progression of knee joint osteoarthrosis in patients with less than 5 years disease duration in a 5-year prospective study
No full textOsteoarthritis: epidemiology, classification, risk factors, and progression, clinical presentation, diagnosis, and treatment
No full textFor the first time, the paper presents in detail the prevalence of osteoarthritis (OA) and considers the predictors of disease development and progression. The clinical classification of OA and its place in the ICD-10 are described. The clinical presentation of the disease is characterized in detail according to the localization of the process. It is noted that there is a change in the understanding of OA as a classic model of nociceptive pain. The paper depicts clinical, laboratory, and instrumental methods for diagnosing the disease, as well as classification and diagnostic criteria; much attention is paid to the current principles of OA therapy according to the Russian clinical recommendations and the guidelines of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the European League Against Rheumatism (EULAR)
The place of nonsteroidal anti-inflammatory drugs in the current osteoarthritis guidelines
No full textThe paper provides a review of the data available in the literature on the relationship of pain to the risk of OA progression. Network analyses and numerous studies, including those conducted at the V.A. Nasonova Research Institute of Rheumatology, have confirmed that pain syndrome is one of the significant predictors of knee OA progression. The major class of medications for OA pain includes nonsteroidal anti-inflammatory drugs. The paper gives data on the efficacy of meloxicam in OA patients, which is widely used in both Russia and other countries of the world. Meloxicam is characterized by a good safety profile in the gastrointestinal tract, cardiovascular and renal systems. It is the drug of choice in patients with musculoskeletal diseases, in particular OA. Good results in severe pain syndrome have been shown by a step-by-step regimen of meloxicam when the injection formulation of the drug is used in the first days of treatment, and then, to consolidate what has been gained from therapy, its oral dosage form is administered in terms of concomitant diseases
MULTIPLE BONE CYSTS CAUSED BY THE INTAKE OF LEFLUNOMIDE IN A FEMALE PATIENT WITH RHEUMATOID ARTHRITIS
No full textThe paper describes a clinical case of adverse reaction (AR) to leflunomide (LEF) in a female patient with rheumatoid arthritis (RA). In 2007 to 2017, the female patient with a reliable diagnosis of RA took LEF (Arava) at a dose of 20 mg/day, which showed a good clinical effect. However, the patient developed atypical bone cysts in the hands, feet, right elbow, and left heel 10 years after start of therapy. The differential diagnosis with deep mycosis, tuberculosis, cancer pathology, endocrine system disease, and AR to the long-term use of LEF was made to clarify the nature of bone cysts
Multimorbidity in osteoarthritis
No full textThis review is focused on the issue of terminology in patients with multiple coexisting diseases in modern clinical practice. We articulate that multimorbidity is one of the leading problems in the field of public healthcare and that the treatment of these patients demands an integral approach derived from the combined nature of the pathology . It was shown that multiple coexisting diseases have a negative effect both on the course of osteoarthritis (OA) and its concomitant ailments, including higher risk of polypharmacy and death. Extra attention is paid to slow-acting symptomatic drugs, which often have positive pleiotropic effects towards both the OA and the concomitant diseases. In particular, there is more and more research showing evidence of the beneficial effects of chondroitin sulfate both on the OA treatment effectiveness as well as on the terms of cardiometabolic prognosis, mitigation of glucose metabolism deficiency and mortality
Autoimmunity and autoinflammation — the key to understanding the pathogenesis of osteoarthritis and developing new ways for its prevention and therapy
No full textThe review considers the full spectrum of currently known autoantigens in osteoarthritis (OA) and discusses their role in the development and/or persistence of synovitis and the initiation of subsequent destruction of articular cartilage with the development of an autoimmune response and auto-inflammation. Of great interest are methods of drug prevention of OA considering autoimmunity responses and associated auto-inflammation, including the use of pharmaconutraceuticals.Preclinical and clinical studies of the safety and efficacy of pharmaconutraceuticals containing native type II collagen are presented. A clear relationship between the composition/chemical structure of the collagen components and its mechanism of action and efficacy is discussed. Taking into account the autoimmune pathogenesis of OA, new combined pharmaconutraceuticals aimed at reducing the manifestations of autoinflammation (chondroitin sulfate, glucosamine sulfate) are developed. They have an optimal ratio of active ingredients with a sufficient level of evidence, which allows enhancing their beneficial pharmacological effects
- …
